1.92
price down icon4.48%   -0.09
after-market 시간 외 거래: 1.91 -0.01 -0.52%
loading
전일 마감가:
$2.01
열려 있는:
$1.95
하루 거래량:
293.53K
Relative Volume:
0.31
시가총액:
$4.36M
수익:
-
순이익/손실:
$-16.77M
주가수익비율:
-0.055
EPS:
-34.9387
순현금흐름:
$-15.08M
1주 성능:
-2.04%
1개월 성능:
+3.23%
6개월 성능:
-83.49%
1년 성능:
-89.59%
1일 변동 폭
Value
$1.8601
$1.95
1주일 범위
Value
$1.8601
$2.12
52주 변동 폭
Value
$1.71
$55.00

Genprex Inc Stock (GNPX) Company Profile

Name
명칭
Genprex Inc
Name
전화
512-537-7997
Name
주소
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
직원
13
Name
트위터
@genprex
Name
다음 수익 날짜
2026-03-30
Name
최신 SEC 제출 서류
Name
GNPX's Discussions on Twitter

Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
GNPX
Genprex Inc
1.92 4.56M 0 -16.77M -15.08M -34.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.05 114.72B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
737.45 78.67B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
684.50 42.38B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
311.10 41.75B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
282.72 31.33B 5.36B 287.73M 924.18M 2.5229

Genprex Inc Stock (GNPX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-01-26 개시 National Securities Buy
2019-04-29 개시 Noble Capital Markets Outperform

Genprex Inc 주식(GNPX)의 최신 뉴스

pulisher
12:58 PM

Genprex collaborators to present lung cancer data at AACR meeting By Investing.com - Investing.com South Africa

12:58 PM
pulisher
Mar 18, 2026

Genprex presents positive preclinical REQORSA data at AACR showing biomarkers and combo efficacy - TradingView

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex Highlights New Reqorsa Preclinical Data at AACR - TipRanks

Mar 18, 2026
pulisher
Mar 18, 2026

GNPX: Genprex Researchers to Present at AACR 2026 with Promising Lung Cancer Data - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex collaborators to present lung cancer data at AACR meeting - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PR Newswire

Mar 18, 2026
pulisher
Mar 13, 2026

New Highs: Will Genprex Inc benefit from green energy policiesTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

Mar 13, 2026
pulisher
Mar 13, 2026

GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill

Mar 13, 2026
pulisher
Mar 10, 2026

Genprex to Participate at BIO Europe Spring 2026 - Barchart

Mar 10, 2026
pulisher
Mar 10, 2026

GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mar 10, 2026
pulisher
Mar 06, 2026

Aug Closing: Will Genprex Inc outperform tech stocksMarket Activity Report & Weekly High Return Forecasts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Trend Recap: Will Genprex Inc outperform tech stocksWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 01, 2026

Genprex receives patent approval in Australia for cancer therapy - Investing.com Nigeria

Mar 01, 2026
pulisher
Feb 28, 2026

GNPX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

Genprex (NASDAQ: GNPX) CMO has shares withheld to cover RSU taxes - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

Genprex (GNPX) CEO reports 9,330-share tax-withholding disposition - Stock Titan

Feb 27, 2026
pulisher
Feb 26, 2026

Congressional Trading Activity Insights - Intellectia AI

Feb 26, 2026
pulisher
Feb 26, 2026

Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy - Indian Pharma Post

Feb 26, 2026
pulisher
Feb 25, 2026

Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Benzinga

Feb 25, 2026
pulisher
Feb 25, 2026

Genprex Advances Cancer Therapy Strategy with Key International Patents - AD HOC NEWS

Feb 25, 2026
pulisher
Feb 24, 2026

Genprex receives Japanese and European patents for cancer therapy By Investing.com - Investing.com India

Feb 24, 2026
pulisher
Feb 23, 2026

Genprex stock jumps on Japan, Europe patent approvals By Investing.com - Investing.com Nigeria

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex stock jumps on Japan, Europe patent approvals - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex receives Japanese and European patents for cancer therapy - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView

Feb 23, 2026
pulisher
Feb 23, 2026

New cancer patents support Genprex (NASDAQ: GNPX) Acclaim-3 trial - Stock Titan

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - Barchart.com

Feb 23, 2026
pulisher
Feb 22, 2026

Genprex Navigates a Pivotal Juncture Amid Clinical Progress and Financial Strain - AD HOC NEWS

Feb 22, 2026
pulisher
Feb 20, 2026

Published on: 2026-02-21 03:40:37 - baoquankhu1.vn

Feb 20, 2026
pulisher
Feb 15, 2026

Will Genprex Inc. benefit from green energy policiesChart Signals & Accurate Trade Setup Notifications - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

How strong is Genprex Inc. (2DE0) stock earnings growth2025 Short Interest & Precise Swing Trade Entry Alerts - mfd.ru

Feb 14, 2026
pulisher
Feb 11, 2026

Genprex receives patent approval in Australia for cancer therapy By Investing.com - Investing.com Canada

Feb 11, 2026
pulisher
Feb 11, 2026

Ayrton Capital-led group reports 9.72% Genprex (GNPX) stake via warrants - Stock Titan

Feb 11, 2026
pulisher
Feb 10, 2026

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - BioSpace

Feb 10, 2026
pulisher
Feb 10, 2026

Genprex (GNPX) Gains Australian Patent Approval for Cancer Treat - GuruFocus

Feb 10, 2026
pulisher
Feb 10, 2026

Genprex Gains Australian Patent Acceptance for REQORSA Therapy - TipRanks

Feb 10, 2026
pulisher
Feb 10, 2026

Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy - TradingView

Feb 10, 2026
pulisher
Feb 10, 2026

Genprex Patent Acceptance and Clinical Trial Expansion - TradingView

Feb 10, 2026
pulisher
Feb 10, 2026

Genprex (NASDAQ: GNPX) advances REQORSA patent strategy and expands Acclaim-3 lung cancer trial - Stock Titan

Feb 10, 2026
pulisher
Feb 09, 2026

Bull Run: Will Genprex Inc benefit from green energy policiesPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn

Feb 09, 2026
pulisher
Feb 06, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Feb 06, 2026
pulisher
Feb 04, 2026

Genprex Shares Seek Catalysts Amid Clinical Trial Focus - AD HOC NEWS

Feb 04, 2026
pulisher
Jan 30, 2026

Institution Moves: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARExit Point & Short-Term Trading Alerts - baoquankhu1.vn

Jan 30, 2026
pulisher
Jan 19, 2026

Aug PreEarnings: Will Genprex Inc outperform tech stocksShort Setup & Safe Entry Point Identification - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 18, 2026

Aug Patterns: Whats the outlook for TMD Energy Limiteds sectorWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 15, 2026

Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative

Jan 15, 2026
pulisher
Jan 15, 2026

Aug Spikes: How does Genprex Inc score in quality rankingsFed Meeting & High Accuracy Investment Signals - baoquankhu1.vn

Jan 15, 2026

Genprex Inc (GNPX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):